Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06650761 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of CDX-622
A Phase 1 study of Healthy Participants, sponsored by Celldex Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
- 1
- Study location
NCT06650761 is a Phase 1 study of Healthy Participants that is active but no longer recruiting, run by Celldex Therapeutics. The registered enrollment target is 85 participants, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (31% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06650761, a Phase 1 study of Healthy Participants, is active but no longer recruiting, sponsored by Celldex Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study to determine the safety of CDX-622 in healthy participants.
Conditions Studied
Interventions
- DRUG Normal Saline
- DRUG CDX-622
Study Locations (1)
Arizona
- Celerion, Inc. - Tempe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2024-11-01 |
| Est. Completion | 2026-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06650761
The ClinicalTrials.gov registry entry for NCT06650761 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (31% higher). The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Normal Saline is the first listed.
NCT06650761 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT06650761 about?
NCT06650761 is a clinical study titled "A Phase I Study of CDX-622". This is a study to determine the safety of CDX-622 in healthy participants.
What is the current status of trial NCT06650761?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2024-11-01. Estimated completion is 2026-04.
What conditions does trial NCT06650761 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT06650761?
The interventions under investigation include: Normal Saline (DRUG), CDX-622 (DRUG).
Who is sponsoring clinical trial NCT06650761?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06650761 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.